iBio (IBIO) Competitors $3.48 -0.15 (-4.13%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$3.56 +0.08 (+2.30%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends IBIO vs. BDTX, CABA, TSVT, KYTX, SGMT, IVA, RENB, TELO, CRBU, and IZTCShould you be buying iBio stock or one of its competitors? The main competitors of iBio include Black Diamond Therapeutics (BDTX), Cabaletta Bio (CABA), 2seventy bio (TSVT), Kyverna Therapeutics (KYTX), Sagimet Biosciences (SGMT), Inventiva (IVA), Renovaro (RENB), Telomir Pharmaceuticals (TELO), Caribou Biosciences (CRBU), and Invizyne Technologies (IZTC). These companies are all part of the "pharmaceutical products" industry. iBio vs. Black Diamond Therapeutics Cabaletta Bio 2seventy bio Kyverna Therapeutics Sagimet Biosciences Inventiva Renovaro Telomir Pharmaceuticals Caribou Biosciences Invizyne Technologies Black Diamond Therapeutics (NASDAQ:BDTX) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings. Is BDTX or IBIO more profitable? Black Diamond Therapeutics' return on equity of -68.08% beat iBio's return on equity.Company Net Margins Return on Equity Return on Assets Black Diamond TherapeuticsN/A -68.08% -49.65% iBio N/A -73.15%-45.51% Which has more risk and volatility, BDTX or IBIO? Black Diamond Therapeutics has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500. Comparatively, iBio has a beta of -3.25, meaning that its stock price is 425% less volatile than the S&P 500. Do insiders & institutionals have more ownership in BDTX or IBIO? 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 8.9% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 0.6% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to BDTX or IBIO? In the previous week, iBio had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 3 mentions for iBio and 2 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.46 beat iBio's score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iBio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation and earnings, BDTX or IBIO? iBio has higher revenue and earnings than Black Diamond Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlack Diamond TherapeuticsN/AN/A-$82.44M-$1.33-1.62iBio$220K156.13-$24.91MN/AN/A Do analysts rate BDTX or IBIO? Black Diamond Therapeutics currently has a consensus price target of $15.50, suggesting a potential upside of 617.59%. iBio has a consensus price target of $4.30, suggesting a potential upside of 23.56%. Given Black Diamond Therapeutics' higher possible upside, equities analysts clearly believe Black Diamond Therapeutics is more favorable than iBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00iBio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in BDTX or IBIO? Black Diamond Therapeutics received 48 more outperform votes than iBio when rated by MarketBeat users. Likewise, 69.86% of users gave Black Diamond Therapeutics an outperform vote while only 42.86% of users gave iBio an outperform vote. CompanyUnderperformOutperformBlack Diamond TherapeuticsOutperform Votes5169.86% Underperform Votes2230.14% iBioOutperform Votes342.86% Underperform Votes457.14% SummaryBlack Diamond Therapeutics beats iBio on 9 of the 13 factors compared between the two stocks. Get iBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBIO vs. The Competition Export to ExcelMetriciBioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$35.85M$7.06B$5.84B$20.30BDividend YieldN/A2.75%4.75%3.64%P/E RatioN/A5.7326.0434.82Price / Sales156.13306.03447.4615.49Price / CashN/A65.6738.0120.26Price / Book2.476.717.644.80Net Income-$24.91M$138.33M$3.18B$1.02B7 Day Performance1.46%-2.63%-2.00%-1.07%1 Month Performance13.36%-2.33%-0.44%-1.11%1 Year PerformanceN/A-5.33%16.44%13.69% iBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBIOiBio0.7421 of 5 stars$3.48-4.1%$4.30+23.6%N/A$35.85M$220,000.000.00100News CoverageBDTXBlack Diamond Therapeutics3.3805 of 5 stars$2.37+1.3%$15.50+554.0%-53.7%$134.10MN/A-1.7890Short Interest ↓Positive NewsCABACabaletta Bio2.2422 of 5 stars$2.71+0.4%$22.71+738.2%-90.7%$132.47MN/A-1.2650Analyst ForecastTSVT2seventy bio2.1813 of 5 stars$2.54-0.4%$7.20+183.5%-53.2%$131.03M$45.62M-1.37440Analyst ForecastNews CoverageKYTXKyverna Therapeutics1.1479 of 5 stars$3.03-0.3%$25.71+748.7%-89.9%$130.81M$7.03M0.0096SGMTSagimet Biosciences1.8145 of 5 stars$4.25-3.4%$23.00+441.2%-38.9%$130.35M$2M0.008IVAInventiva2.0097 of 5 stars$2.47-0.4%$13.25+436.4%-13.1%$129.63M$18.91M0.00100Analyst ForecastNews CoverageGap UpRENBRenovaro0.763 of 5 stars$0.81+9.0%N/A-61.1%$128.39MN/A-0.8420Earnings ReportNews CoverageGap UpTELOTelomir Pharmaceuticals2.2818 of 5 stars$4.29+0.5%N/A-54.8%$127.67MN/A-7.401Analyst ForecastNews CoverageCRBUCaribou Biosciences3.1342 of 5 stars$1.35+3.1%$10.33+665.4%-80.8%$122.25M$11.48M-0.82100Gap UpIZTCInvizyne TechnologiesN/A$19.42+0.7%N/AN/A$121.38MN/A0.00N/A Related Companies and Tools Related Companies BDTX Alternatives CABA Alternatives TSVT Alternatives KYTX Alternatives SGMT Alternatives IVA Alternatives RENB Alternatives TELO Alternatives CRBU Alternatives IZTC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:IBIO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IBIO Stock Alerts